Table 2.

Breast cancer anticancer medicines scored with ESMO-MCBS^a

Medicines	Setting	ESMO-MCBS score	References
Chemotherapy + trastuzumab	Adjuvant or neoadjuvant HER2-positive tumours	A	9
Trastuzumab and docetaxel + pertuzumab	Neoadjuvant HER2-overexpressed invasive ductal breast	Cb	10,11
Trastuzumab + docetaxel + pertuzumab	First line metastatic	4	12, 13, 14, 15
Lapatinib + trastuzumab	Third line metastatic	4	16,17
Fulvestrant + palbociclib	Metastatic HR-positive, HER2-negative second line	4	18
T-DM1	Second line metastatic after trastuzumab failure	4	19,20
Letrozole + palbociclib	Metastatic HR-positive, HER2-negative first line	3	21
Letrozole + palbociclib	Metastatic HR-positive, HER2-negative first line	3b	22
Letrozole + ribociclib	First line metastatic post-menopause ER/PR positive	3	23
Capecitabine + lapatinib	Second line metastatic after trastuzumab failure	3	24
Paclitaxel + bevacizumab	First line metastatic, no crossover	2	25
Exemestane + everolimus	Metastatic after failure of aromatase inhibitor (with PFS >6 months), no crossover	2	26
Eribulin	Third line metastatic after anthracycline and taxane	2	27
Eribulin	Third line metastatic after anthracycline and taxane in patients with HER2-negative tumours	1	28

Included in the Kazakhstan’s list of medicines (Bolded).

ESMO-MCBS, ESMO-Magnitude of Clinical Benefit Scale; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; PFS, progression-free survival; PR, progesterone receptor; T-DM1, trastuzumab emtansine.

^aData 2017.

^bRandomised phase II study.